Table 1.
Sample | Control Group 1 (Healthy Donors) | Control Group 2 (Patients with Obesity without T2DM) | Patients with T2DM before LSG | Patients with T2DM after LSG | Patients with T2DM before RYGB | Patients with T2DM after RYGB | |
---|---|---|---|---|---|---|---|
Group | 1 | 2 | 3 | 4 | 5 | 6 | |
Anthropometric and Biochemical Parameters | Age (years) | 41.8 ± 4.6 | 42.8 ± 8.3 | 48 ± 8.6 | 49 ± 8.6 | 47 ± 9.4 | 48 ± 9.4 |
Sex (m/w) | 8/10 | 9/18 | 5/16 | 5/16 | 6/19 | 6/19 | |
BMI (kg/m2) | 22.5 ± 3.01 | 36 ± 3.45 p1-2 < 0.001 * |
53.9 ± 8.98 p1-3 < 0.001 * p2-3 < 0.001 * |
37.11 ± 6.22 p1-4 = 0.001 * p3-4 < 0.001 * |
43.26 ± 7.0 p1-5 < 0.001 * p2-5 < 0.001 * |
31.68 ± 5.2 p1-6 = 0.001 * p5-6 < 0.001 * |
|
EWL (%) | - | - | - | 53.15 (40.08–62.24) | - | 60.20 (47.66–70.63) | |
mtDNA (copy number) | 206.5 (165–228.2) | 164.0 (135.7–231.5) | 149.0 (115.0–180) p1-3 = 0.023 * |
194.5 (125.8–486.2) p3-4 = 0.011 * |
155 (132–202) | 231 (185.8–352) p2-6 = 0.002 * p5-6 = 0.007 * |
|
Fasting serum glucose level (mmol/L) | 4.9 (4.64–5.34) | 5.89 (5.6–6.76) | 8.1 (6.87–9.08) p1-3 < 0.001 * p2-3 < 0.001 * |
4.99 (4.7–5.26) p3-4 < 0.001 * p2-4 < 0.013 * |
8.61 (6.36–9.07) p1-5 = 0.001 * p2-5 = 0.013 * |
5.5 (5.13–6.30) p5-6 = 0.002 * |
|
Insulin (pg/mL) | 44.8 (32.49–54.48) | 119 (55.2–193.7) p1-2 = 0.002 * |
140 (105.57–454.75) p1-3 = 0.011 * |
145.13 (64.5–238.22) p1-4 = 0.041 * |
469.0 (161.4–767.3) p1-5 = 0.001 * p2-5 = 0.014 * |
60.48 (36.95–303.21) p5-6 = 0.043 * |
|
HbA1c (%) | 5.5 (3.5–5.8) | 5.81 (5.6–5.9) | 6.7 (6.12–7.9) p1-3 = 0.008 * p2-3 < 0.05 * |
5.5 (4.7–6.0) p3-4 < 0.05 * |
8.05 (6.5–9.9) p1-5 < 0.05 * p2-5 < 0.05 * |
5.7 (5.0–6.6) p5-6 < 0.05 * |
Note: * p < 0.05, differences in significance level were determined using the Wilcoxon test for two dependent samples and Mann-Whitney criterion for two independent samples; percentage of excess weight loss (%EWL); (Mean ± SD) for normal distributions (Me(Q1–Q3)) for non-normal distributions.